Keryx Biopharmaceuticals Inc. (KERX) Given “Market Perform” Rating at FBR & Co
FBR & Co restated their market perform rating on shares of Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) in a report released on Tuesday. They currently have a $7.00 target price on the biopharmaceutical company’s stock.
A number of other analysts have also recently weighed in on KERX. Maxim Group reiterated a buy rating and set a $9.00 price target (up from $7.00) on shares of Keryx Biopharmaceuticals in a research report on Friday, July 8th. Zacks Investment Research upgraded Keryx Biopharmaceuticals from a hold rating to a buy rating and set a $8.00 price target on the stock in a research report on Wednesday, July 13th. Stifel Nicolaus cut Keryx Biopharmaceuticals from a buy rating to a hold rating in a research report on Tuesday, August 2nd. Brean Capital cut Keryx Biopharmaceuticals from a buy rating to a hold rating in a research report on Tuesday, August 2nd. Finally, Ladenburg Thalmann increased their price target on Keryx Biopharmaceuticals from $9.00 to $10.00 and gave the stock a buy rating in a research report on Tuesday, August 2nd. One analyst has rated the stock with a sell rating, eight have given a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of Hold and a consensus price target of $8.44.
Shares of Keryx Biopharmaceuticals (NASDAQ:KERX) traded down 1.77% during trading on Tuesday, reaching $4.43. The company had a trading volume of 191,051 shares. The stock’s market capitalization is $469.11 million. Keryx Biopharmaceuticals has a 12 month low of $2.80 and a 12 month high of $7.80. The stock’s 50-day moving average price is $4.87 and its 200-day moving average price is $5.47.
Keryx Biopharmaceuticals (NASDAQ:KERX) last announced its quarterly earnings results on Monday, August 1st. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by $0.14. The company had revenue of $9.30 million for the quarter, compared to analyst estimates of $8.60 million. Keryx Biopharmaceuticals had a negative return on equity of 172.04% and a negative net margin of 590.50%. The firm’s revenue for the quarter was up 272.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.26) earnings per share. Equities analysts forecast that Keryx Biopharmaceuticals will post ($1.24) earnings per share for the current fiscal year.
In other news, CFO Scott A. Holmes sold 4,935 shares of the stock in a transaction on Friday, July 29th. The stock was sold at an average price of $7.36, for a total value of $36,321.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 3.08% of the stock is owned by insiders.
Several hedge funds have recently added to or reduced their stakes in KERX. Alpine Partners VI LLC purchased a new stake in shares of Keryx Biopharmaceuticals during the second quarter valued at about $110,000. Trexquant Investment LP purchased a new stake in shares of Keryx Biopharmaceuticals during the second quarter valued at about $115,000. Cambridge Investment Research Advisors Inc. raised its stake in shares of Keryx Biopharmaceuticals by 38.2% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 18,100 shares of the biopharmaceutical company’s stock valued at $120,000 after buying an additional 5,000 shares in the last quarter. LMR Partners LLP purchased a new stake in shares of Keryx Biopharmaceuticals during the second quarter valued at about $125,000. Finally, Stifel Financial Corp purchased a new stake in shares of Keryx Biopharmaceuticals during the second quarter valued at about $170,000. Institutional investors own 61.15% of the company’s stock.
Keryx Biopharmaceuticals Company Profile
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. The Company’s product Auryxia (ferric citrate), also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron-based compound, which is indicated for the control of serum phosphorus levels in patients with chronic kidney disease (CKD), on dialysis.
Receive News & Stock Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related stocks with our FREE daily email newsletter.